A major award has been given to an international consortium which has developed a new vaccine against hepatitis C, and will be declared “ConsolationIST winners” in the field of cell and molecular biology (CVBM) research.
Dr. Hernando A. de Macedo and his colleagues had already developed a vaccine that protected monkeys against hepatitis C genotype C virus (HCGV-C), and this is the first experimental human clinical trial involving in vaccinated monkeys.
The achievement of this CEUBIA award and the subsequent award of CEUBIA “consolationist” honour at the 17th European Congress on Cytomegalovirus (ECCV) Research & International Technology 2019 (ECCT) in Split, Belgium, underlines the strides being made by the Macedo Lab in the field of virus research.
This CEUBIA award is recognizing the team’s contribution to the field of blood & plasma research, as well as bringing attention to the important work done by the Macedo Lab over the last 10 years in accelerating advances in the development of the science of virus biology, Control of virally acquired disorders such as hepatitis C and hepatitis C H1, & C, & 925, clinical trials for diagnostics, prevention, treatments, etc.
“It is a very difficult issue, with very little progress being made, as far as in the vaccine against hepatitis C virus (HCV-C) is concerned,” told the CEUBIA acronym award winners:
Cornelia Heinzel & CIEUBIA, Brussel, Belgium.
This award also highlights the team’s plans to launch a centre in the Netherlands to promote research and practical applications of the research findings, produced in the Macedo Lab and the Europe General Hospital (EGH) in Amsterdam, the Netherlands. In addition, the CEUBIA 2.0 Award is also presented.
The Macedo Lab is based at the University of Oxford and has been working intensively with partners for the last 10 years on viruses with currently known gene ends. “We are continuing to study virus gene hijacking,” explains Claudia Macedo Le Couteur, head of the project management department of the Macedo Lab (Institut Pasteur/Université de Paris). “To our surprise, when we started to draw conclusions about the efficacy and tolerability of this approach, it was the case that was already in use throughout Europe: Avigan or Nipah virus, Cuba virus, Culex virus and Portland virus among others.”
The expert group stresses that it is a Polish or international consortium addition, and that the Macedo Lab would continue to work collaboratively with different grantees and governments.